Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Small Cohort 2 sub-trial to obtain exploratory data on the expanded dose response of IMU-838.

X
Trial Profile

Small Cohort 2 sub-trial to obtain exploratory data on the expanded dose response of IMU-838.

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Mar 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vidofludimus calcium (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors Immunic
  • Most Recent Events

    • 26 Mar 2021 According to an Immunic media release, An unblinded interim analysis of selected MRI data is planned after all Cohort 2 patients have completed week 12 MRI assessments. company expects this data to be available at the end of March or in early April 2021.
    • 15 Nov 2020 New trial record
    • 05 Nov 2020 According to an Immunic media release, the still-active sites of the phase 2 trial of IMU-838 in RRMS continue to be used and, as a result,this assessment can be executed in an accelerated fashion.It is expected to provide additional data to address any potential regulatory requests in the context of the design of a phase 3 program. Management believes that this strategy will enable risk reduction for end-of-phase 2 discussions with regulatory agencies.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top